The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer

被引:6
作者
Bragina, Olga D. [1 ,2 ]
Deyev, Sergei M. [2 ,3 ]
Chernov, Vladimir, I [1 ,2 ]
Tolmachev, Vladimir M. [2 ,4 ]
机构
[1] Russian Acad Sci, Canc Res Inst, Tomsk Natl Res Med Ctr, Tomsk 634009, Russia
[2] Natl Res Tomsk Polytech Univ, Tomsk 634050, Russia
[3] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[4] Uppsala Univ, Uppsala, Sweden
来源
ACTA NATURAE | 2022年 / 14卷 / 02期
关键词
breast cancer; HER2/neu; radionuclide diagnostics; monoclonal antibody; alternative scaffold proteins; HER2; EXPRESSION; THERAPEUTIC TARGETS; RECEPTOR; THERANOSTICS; TRASTUZUMAB; DISCORDANCE; CONCORDANCE; METASTASES; BIOMARKERS; GUIDELINES;
D O I
10.32607/actanaturae.11611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review examines the evolution of the radionuclide diagnosis of HER2-positive breast cancer using various compounds as a targeting module in clinical practice: from full-length antibodies to a new group of small synthetic proteins called alternative scaffold proteins. This topic is of especial relevance today in view of the problems attendant to the detection of breast cancer with HER2/neu overexpression, which, in most cases, introduce errors in the treatment of patients. The results of clinical studies of radiopharmaceuticals based on affibody molecules, ADAPTs, and DARPins for SPECT and PET have demonstrated good tolerability of the compounds, their rapid excretion from the body, and the possibility to differentiate tumor sites depending on the HER2/neu status. This indicates that targeted radionuclide diagnosis holds promise and the need to continue research in this direction.
引用
收藏
页码:4 / 15
页数:12
相关论文
共 88 条
  • [1] Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
    Agersborg, Sally
    Mixon, Christopher
    Thanh Nguyen
    Aithal, Sramila
    Sudarsanam, Sucha
    Blocker, Forrest
    Weiss, Lawrence
    Gasparini, Robert
    Jiang, Shiping
    Chen, Wayne
    Hess, Gregory
    Albitar, Maher
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (02) : 321 - 328
  • [2] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
    Ahn, Soomin
    Woo, Ji Won
    Lee, Kyoungyul
    Park, So Yeon
    [J]. JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2020, 54 (01) : 34 - 44
  • [3] Tumor-targeted nanomedicines for cancer theranostics
    Arranja, Alexandra G.
    Pathak, Vertika
    Lammers, Twan
    Shi, Yang
    [J]. PHARMACOLOGICAL RESEARCH, 2017, 115 : 87 - 95
  • [4] Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules
    Baum, Richard P.
    Prasad, Vikas
    Mueller, Dirk
    Schuchardt, Christiane
    Orlova, Anna
    Wennborg, Anders
    Tolmachev, Vladimir
    Feldwisch, Joachim
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (06) : 892 - 897
  • [5] Behr TM, 2001, NEW ENGL J MED, V345, P995
  • [6] Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer
    Beylergil, Volkan
    Morris, Patrick G.
    Smith-Jones, Peter M.
    Modi, Shanu
    Solit, David
    Hudis, Clifford A.
    Lu, Yang
    O'Donoghue, Joseph
    Lyashchenko, Serge K.
    Carrasquillo, Jorge A.
    Larson, Steven M.
    Akhurst, Timothy J.
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2013, 34 (12) : 1157 - 1165
  • [7] Possibilities of radionuclide diagnostics of Her2-positive breast cancer using technetium-99m-labeled target molecules: the first experience of clinical use
    Bragina, O. D.
    Chernov, V., I
    Garbukov, E. Yu
    Doroshenko, A., V
    Vorobyeva, A. G.
    Orlova, A. M.
    Tolmachev, V. M.
    [J]. BYULLETEN SIBIRSKOY MEDITSINY, 2021, 20 (01): : 23 - 30
  • [8] Alternative scaffolds in radionuclide diagnosis of malignancies
    Bragina, O. D.
    Chernov, V., I
    Zeltchan, R., V
    Sinilkin, I. G.
    Medvedeva, A. A.
    Larkina, M. S.
    [J]. BYULLETEN SIBIRSKOY MEDITSINY, 2019, 18 (03): : 125 - 133
  • [9] Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
    Bragina, Olga
    Chernov, Vladimir
    Schulga, Alexey
    Konovalova, Elena
    Garbukov, Eugeniy
    Vorobyeva, Anzhelika
    Orlova, Anna
    Tashireva, Liubov
    Sorensen, Jens
    Zelchan, Roman
    Medvedeva, Anna
    Deyev, Sergey
    Tolmachev, Vladimir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (04) : 528 - 535
  • [10] Phase I Study of 99mTc-ADAPT6, a Scaffold Protein-Based Probe for Visualization of HER2 Expression in Breast Cancer
    Bragina, Olga
    von Witting, Emma
    Garousi, Javad
    Zelchan, Roman
    Sandstrom, Mattias
    Orlova, Anna
    Medvedeva, Anna
    Doroshenko, Artem
    Vorobyeva, Anzhelika
    Lindbo, Sarah
    Borin, Jesper
    Tarabanovskaya, Natalya
    Sorensen, Jens
    Hober, Sophia
    Chernov, Vladimir
    Tolmachev, Vladimir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 493 - 499